Summary
Most claims are about combining lisinopril and losartan (ACE inhibitor + ARB), but the provided label text is for lisinopril/hydrochlorothiazide and contains no information supporting those combination-with-losartan safety assertions. Several statements are unsupported or not evaluable from the supplied prescribing information.
Category Scores
Accurate Statements
Lisinopril is an angiotensin-converting enzyme (ACE) inhibitor.
UNSUPPORTED: The supplied label excerpt provided does not state that lisinopril is an ACE inhibitor.
Losartan is an angiotensin II receptor blocker (ARB).
UNSUPPORTED: The supplied label excerpt provided does not mention losartan or describe ARBs.
Unsupported Statements
Lisinopril and losartan are not safe to take together.
No supplied prescribing information addresses combining lisinopril with losartan.
ACE inhibitors and ARBs target the same renin-angiotensin-aldosterone system (RAAS) pathway to lower blood pressure.
No such RAAS/pathway statement is present in the provided label text.
Combining an ACE inhibitor and an ARB increases the risk of serious harm without added benefit over using one alone.
No provided label information evaluates ACE inhibitor + ARB combination benefit/risk, or mentions losartan.
The primary danger of combining an ACE inhibitor and an ARB is acute kidney injury.
The supplied label excerpts provided do not discuss acute kidney injury risk for ACE inhibitor + ARB dual therapy.
Acute kidney injury from excessive RAAS suppression can occur rapidly.
No provided label text addresses RAAS suppression timing or acute kidney injury for ACE inhibitor + ARB use.
Excessive RAAS suppression can reduce kidney blood flow.
No provided label text supports this mechanism.
Excessive RAAS suppression can elevate creatinine levels.
No provided label text supports this in the context of ACE inhibitor + ARB dual therapy.
Excessive RAAS suppression can lead to potential kidney failure.
No provided label text supports this for ACE inhibitor + ARB dual therapy.
Combining an ACE inhibitor and an ARB can cause severe hypotension.
The provided label excerpt mentions hypotension in adverse experiences for lisinopril/hydrochlorothiazide, but does not address ACE inhibitor + ARB combination with losartan.
Severe hypotension can cause dizziness, fainting, or shock.
The provided label excerpt does not link severe hypotension to these specific outcomes for lisinopril/losartan combination.
Combining an ACE inhibitor and an ARB can cause hyperkalemia.
The supplied label excerpt provided does not mention hyperkalemia in the context of ACE inhibitor + ARB dual therapy.
Hyperkalemia can trigger dangerous heart rhythms.
No provided label text supports this statement.
Angioedema (swelling of the face, throat, or airways) can occur.
While angioedema is referenced in the provided CONTRAINDICATIONS and WARNINGS anchor, the specific occurrence statement for ACE inhibitor + ARB combination with losartan is not supported by the provided excerpt.
Angioedema is more common with ACE inhibitors like lisinopril.
No provided label text quantifies or compares angioedema incidence by drug class or lists losartan comparisons.
Dual therapy can worsen angioedema.
No provided label text supports angioedema worsening with ACE inhibitor + ARB combination.
The risks of combining an ACE inhibitor and an ARB are dose-dependent.
No provided label text supports dose-dependence for ACE inhibitor + ARB combination.
The risks hit harder in patients with dehydration.
No provided label text supports this risk modifier in the context of ACE inhibitor + ARB combination.
The risks hit harder in patients with heart failure.
No provided label text supports this risk modifier.
The risks hit harder in patients with diabetes.
No provided label text supports this risk modifier.
The risks hit harder in patients with pre-existing kidney issues.
No provided label text supports this risk modifier for ACE inhibitor + ARB combination.
Combination use of an ACE inhibitor and an ARB is rare.
No provided label text supports frequency/rarity of ACE inhibitor + ARB dual therapy.
Combination use is described as short-term and in specific cases like resistant hypertension or heart failure.
No provided label text addresses ACE inhibitor + ARB dual therapy duration/indications such as resistant hypertension or heart failure.
Short-term dual therapy should be under close monitoring.
No provided label text provides monitoring instructions for ACE inhibitor + ARB dual therapy.
Short-term dual therapy requires frequent blood tests for kidney function and electrolytes.
No provided label text provides such monitoring instructions for lisinopril + losartan.
Guidelines strongly advise against routine dual therapy of ACE inhibitor plus ARB.
No provided prescribing information includes guideline statements.
Guidelines favor single-agent therapy or other combinations like an ACE inhibitor with a calcium channel blocker.
No provided prescribing information discusses guidelines or alternative combinations involving calcium channel blockers.
Symptoms from taking lisinopril and losartan together may appear within hours to days.
No provided label text supports onset timing for lisinopril + losartan combination adverse effects.
Symptoms may include fatigue, nausea, confusion, irregular heartbeat, or swelling.
The provided label text includes adverse experiences for lisinopril/hydrochlorothiazide, but does not link these symptoms to lisinopril + losartan ingestion, nor does it mention confusion/irregular heartbeat as specific expected symptoms for that combination.
Stopping both drugs immediately and seeking emergency care is advised if taken together by mistake.
No provided label text provides instructions for inadvertent lisinopril + losartan ingestion.
Dialysis may be needed in severe cases of harm from taking lisinopril and losartan together.
No provided label text discusses dialysis for lisinopril + losartan harm.
Long-term harm from taking lisinopril and losartan together can cause permanent kidney damage.
No provided label text addresses long-term/permanent kidney damage from lisinopril + losartan combination.
FDA has issued a Drug Safety Communication about a temporary increase in risk for acute kidney injury in patients using both ACE inhibitors and ARBs.
No provided label text includes or references FDA Drug Safety Communications.
Weekly blood work initially is expected for short-term dual therapy.
No provided label text supports this monitoring schedule for ACE inhibitor + ARB dual therapy.
For short-term dual therapy, blood work may then be done biweekly.
No provided label text supports this monitoring schedule.
Short-term dual therapy monitoring includes tracking serum creatinine.
No provided label text provides creatinine monitoring instructions for ACE inhibitor + ARB dual therapy.
In short-term dual therapy, serum creatinine should not rise by more than 30%.
No provided label text includes a creatinine rise threshold percentage.
Short-term dual therapy monitoring includes tracking potassium.
No provided label text provides potassium monitoring instructions for ACE inhibitor + ARB dual therapy.
In short-term dual therapy, potassium should be less than 5.5 mEq/L.
No provided label text includes a potassium numeric threshold or monitoring parameters for ACE inhibitor + ARB dual therapy.
Short-term dual therapy monitoring includes tracking blood pressure.
No provided label text provides monitoring parameters for ACE inhibitor + ARB dual therapy.
Dual therapy should be stopped if kidney function worsens.
No provided label text provides stop criteria for ACE inhibitor + ARB dual therapy with losartan.
Contradictions
Important Omissions
Label-relevant contraindications/precautions applicable to the provided product: hypersensitivity/angioedema related to prior ACE inhibitor therapy; hereditary/idiopathic angioedema; and hydrochlorothiazide-related contraindications (anuria; hypersensitivity to other sulfonamide-derived drugs).
Importance:
Moderate
Dosage/administration and adverse reaction information actually present in the supplied label for lisinopril/hydrochlorothiazide (e.g., starting monotherapy before combination; most frequent adverse experiences; and mention to see WARNINGS for angioedema/excessive hypotension or syncope).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
The response makes many specific safety, timing, monitoring, and management claims about taking lisinopril with losartan that are not supported by the provided prescribing information (which instead addresses lisinopril/hydrochlorothiazide). This mismatch could mislead decision-making.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
The provided label text does not contain information about lisinopril + losartan (ACE inhibitor + ARB) combination therapy, yet the response provides extensive specific claims and monitoring thresholds for that scenario.
Suggested Improvement
Limit evaluation/claims strictly to what is in the supplied label excerpt (lisinopril/hydrochlorothiazide). Remove or clearly qualify statements about lisinopril + losartan, RAAS suppression, AKI timing, dialysis, specific lab thresholds, and FDA communication/guideline assertions that are not supported by the provided prescribing information.